Molecular subtypes redefining treatment algorithms in aggressive and indolent lymphomas?
Should MRD negativity become a standard endpoint in CLL management?
Next-gen agents BTK I (non-covalent BTKi) in relapsed/refractory CLL.
Bispecific antibodies: Mosunetuzumab and glofitamab in B-cell lymphomas.
BCL2 inhibitors: Venetoclax-based regimens in CLL and mantle cell lymphoma.
What are the sequencing strategies for BTK and BCL2 inhibitors in CLL?
Comparing bispecifics to CAR-T in terms of efficacy and accessibility?

1. Peri-operatives CH-IO
2. Locally advanced NSCLC, Management approach
3. First-Line Treatment AGA
4. IO duration-biomarker
5. First Line EGFR+, Second Line EGFR +
6. First Line exon20 Ins
7. 1st ALK treatment
8. K-RAS management

Prostate cancer:
The evolving role of PSMA-targeted radioligand imaging and therapy in prostate cancer
Feasibility of PARPi as upfront therapy in MCRPC
ARPI in high risk localized cancer and in biochemical relapse in NMCSPC
Outcome of triple therapy in MCSPC

Bladder cancer:
Expansion the role of IO in NMIBC, localized MIBC
Approach for 1st line in metastatic TCC , roie of biomatrkers, pPRO
Treatment sequencing in TCC
Genomic profiling directed treatment and ADCs in TCC

Kidney caner:
Validity of Adjuvant IO in RCC ,
Approach to 1st line treatment in ccRCC
Sequencing of subsequent lines
Approach to nCCRCC.
Ole of markers and genomic profile in RCC ( VHL directed treatment)

Integration of the genomic tests in breast cancer , when and for whom
Role of new radionuclide based imaging, in breast cancer imaging
Expanding the role of CDK4/6 in HR+ ve early breast cancer
New role of oral SERD in HR+ ve breast cancer, pre progression and post progression on CDK4/6i
Expanding the role of Anti PIK3CA in breast cancer, in first line with CDK4/6 and post CDK4/6i failure
AKT inhibitor as an acceptable choice post CDK4/6i
Expanding the role of T-Dxd in perioperative setting in HER2 positive breast cancer (DB-05&DB-11)
Paradigm change in first line of advanced/metastatic HER2 positive breast cancer
TKI and how to sequence treatment lines in HER2new positive breast cancer
Immunotherapy in TNBC what did we achieved so far
Expanding role of ADCs in TNBC in first and subsequent lines in TNBC
ADCs in HR+ve breast cancer (Tropics&Tropion breast-02)
Breast cancer Vaccines
Topics arise from ESMO 25 and SABCS 25 (evERA Breast Cancer Study, aphinity final results..etc)

Colorectal Cancer:
Colon cancer incidence increase, and shift to younger age, how to decrease it
Genomic profiling , timing, approach, and requirements
First line, paradigm shift in era of anti BRAF (Breakwater trial), AntiHER2, Anti RAS (CODEBREAK300)
Second line, paradigm shift in era of anti BRAF (BIACON TRIAL), AntiHER2 (MOUNTAINEER, HERCLES-A) , Anti RAS (CHRYSTAL1, CODEBREAk101)
Third Line paradigm Shift in era of anti BRAF, AntiHER2 (DESTINY-CRC01, TRIUMPH), Anti RAS
Rechallange versus 3rd line treatment and impact of Danish trial of lonsurf and bevacizumab on common practice
Preoperative chemotherapy role and when
Preopearative Immunotherapy should we adapt, including possible changes in adjuvant treatment (Atomic trial)
Metastatectomy how far should we go
TNT best use and sequencing

Gastric Cancer:
Does Perioperative immunotherapy, reshape treatment approach in localized gastric and GEJ cancer.
How IO in advanced setting,improved outcome
Approach and selecting combination based on Pd-L1 %
Car-T cell may be a reality in third line in metastaic gastric cancer

HCC:
Applicable combinations in local treatment approaches.
How to choose among the available options.

Cholangio-carcinoma:
Approach to first line treatment
Considerations regarding treatment approaches for different biliary tract carcinoma sites
Second line options hopes vs reality

Pancreas:
Impact of NAPOLI 3 , and POLO trial on practice